Effectiveness and tolerability of immunosuppressants and monoclonal antibodies in preventive treatment of neuromyelitis optica spectrum disorders: A systematic review and network meta-analysis-Reference-Cited by-同舟云学术

Effectiveness and tolerability of immunosuppressants and monoclonal antibodies in preventive treatment of neuromyelitis optica spectrum disorders: A systematic review and network meta-analysis

Published:2019-10 Issue: Volume:35 Page:246-252
ISSN:2211-0348
Container-title:Multiple Sclerosis and Related Disorders
language:en
Short-container-title:Multiple Sclerosis and Related Disorders

Author:

Huang Wenjuan,Wang Liang,Zhang Baojingzi,Zhou Lei,Zhang Tiansong,Quan Chao

Funder

National Natural Science Foundation of China

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology,General Medicine

Reference57 articles.

1. The effect of cyclophosphamide on the immune system: implications for clinical cancer therapy;Ahlmann;Cancer Chemother. Pharmacol.,2016

2. Mycophenolate mofetil and its mechanisms of action;Allison;Immunopharmacology,2000

3. Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study;Araki;Neurology,2014

4. The contribution of cyclosporine a to the understanding and treatment of autoimmune diseases;Bach;Transplant. Proc.,1999

5. Cyclosporine A: a review of current oral and intravenous delivery systems;Beauchesne;Drug Dev. Ind. Pharm.,2007

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Traditional first-line treatment failure rates in neuromyelitis optica spectrum disorder patients included in the Argentinean registry (RelevarEM);Multiple Sclerosis and Related Disorders;2024-09

2. Therapeutic Approach to Autoimmune Neurologic Disorders;CONTINUUM: Lifelong Learning in Neurology;2024-08

3. Rituximab Therapy for Immune-Mediated Neurological Diseases: Our Experience at a Tertiary Care Centre;Cureus;2024-06-12

4. Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management;Journal of Neurology;2023-09-07

5. Overlap syndrome of anti-aquaporin 4 positive neuromyelitis optica spectrum disorder and primary Sjögren’s syndrome: a systematic review of individual patient data;Rheumatology International;2023-07-27